Glycosyn Health Initiatives (GHI) is a not-for-profit 501(c)3 corporation dedicated to implementing new treatments and technologies to reduce the impact of infant and childhood diseases worldwide. It builds on the groundbreaking scientific discoveries of Glycosyn LLC.

A collaboration of scientists from Harvard Medical School/Boston College, Cincinnati Children’s Hospital, and Instituto Nacional de Sciencias Medicas y Nutricion (Mexico) discovered a class of glycan molecules from human milk (human milk oligosaccharides, or hMOS) that inhibit the major causes of diarrhea and may have a significant impact on childhood respiratory diseases. In 2002, these scientists and others established Glycosyn LLC of Medford, Massachusetts to devise a means of manufacturing these molecules at large scale using advanced biotechnology.

GHI was formed as a not-for-profit corporation to distribute these new therapeutics and other inventions to enhance infant and child health for the developing countries. GHI is dedicated to providing Glycosyn’s products at minimum cost to children throughout the world, focusing on developing countries with the highest incidence of childhood diarrhea and respiratory diseases.

GHI is currently building distribution and production relationships in the developing world to prepare for global availability of kiloton quantities of its synthesized hMOS products. GHI seeks support from individuals and institutions who share our dedication to saving the lives of children throughout the developing world.